Arix leads $152 million Series B financing for Pyxis Oncology

  • rix announces a new portfolio company, Pyxis Oncology, with a 5.6% ownership stake
  • Series B proceeds will enable Pyxis to advance differentiated antibody-drug conjugate (ADC) and immune oncology programmes to next value inflection point
  • Arix Managing Director Christian Schetter will join the Pyxis Board of Directors

LONDON, 30 March 2021: Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it has invested in Pyxis Oncology (“Pyxis”), a new portfolio company. As part of the financing, Arix Managing Director Christian Schetter will join the Pyxis Board of Directors.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH